A Phase 1, Double-Blind, Placebo-Controlled, Randomized Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Exploratory Pharmacodynamics of Oral BMS-986318 Administration in Healthy Participants
Latest Information Update: 17 Jan 2020
At a glance
- Drugs BMS 986318 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 10 Jan 2020 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
- 11 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 13 Sep 2019 New trial record